<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258401</url>
  </required_header>
  <id_info>
    <org_study_id>CASE2Z05</org_study_id>
    <nct_id>NCT00258401</nct_id>
  </id_info>
  <brief_title>Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.</brief_title>
  <official_title>The Effectiveness of a Low-Residue Diet on Diarrhea in Cancer Patients Receiving Pelvic Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Eating a diet low in residue (fiber, fat, and certain milk or vegetable products)&#xD;
      may help prevent or reduce diarrhea caused by pelvic radiation therapy.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying a low-residue diet to see how well it&#xD;
      works compared to no dietary intervention in treating diarrhea in patients who are undergoing&#xD;
      radiation therapy to the pelvis for uterine, cervical, or prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the nutritional status, Common Toxicity Criteria (CTC) score, and fecal&#xD;
           incontinence quality of life (FI-QOL) in patients with uterine, cervical, or prostate&#xD;
           cancer who are undergoing pelvic radiotherapy receiving a low-residue diet vs no dietary&#xD;
           intervention.&#xD;
&#xD;
        -  Compare changes in the CTC score and FI-QOL in patients receiving a low-residue diet vs&#xD;
           no dietary intervention.&#xD;
&#xD;
        -  Compare the efficacy, in terms of a lower CTC score or higher perceived FI-QOL, of a&#xD;
           low-residue diet vs no dietary intervention in these patients.&#xD;
&#xD;
      OUTLINE: This is a parallel, randomized, controlled, pilot study. Patients are stratified&#xD;
      according to cancer type. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      All patients are interviewed to obtain a baseline grade of diarrhea (according to NCI's&#xD;
      Common Toxicity Criteria [CTC] scale) and dietary history and measure Fecal Incontinence&#xD;
      Quality of Life (FI-QOL).&#xD;
&#xD;
        -  Arm I (intervention): At the onset of diarrhea symptoms, patients are instructed to eat&#xD;
           a low-residue diet. Patients continue on this diet for 2-4 weeks. They are interviewed&#xD;
           weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events,&#xD;
           FI-QOL, and changes in CTC scores.&#xD;
&#xD;
        -  Arm II (control): Patients undergo no dietary intervention but are interviewed as in arm&#xD;
           I.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diarrhea as assessed by Fecal Incontinence Questionnaire and CTC v3.0 at baseline and once a week for 6 weeks</measure>
    <time_frame>baseline and once a week for 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Diarrhea</condition>
  <condition>Prostate Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>low-residue diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no dietary intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.</description>
    <arm_group_label>low-residue diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <description>Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.</description>
    <arm_group_label>low-residue diet</arm_group_label>
    <arm_group_label>no dietary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.</description>
    <arm_group_label>low-residue diet</arm_group_label>
    <arm_group_label>no dietary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of uterine, cervical, or prostate cancer&#xD;
&#xD;
          -  Current patient at the Ireland/Case Comprehensive Cancer Center&#xD;
&#xD;
          -  Planning pelvic radiation therapy within the next 4 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No enteric support&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent illness or medical condition that would preclude study compliance&#xD;
&#xD;
          -  No history of allergies or dietary intolerances (e.g., lactose intolerance) that would&#xD;
             preclude study treatment or interfere with study results&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed (e.g., testosterone suppression)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior colectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent glutamine, psyllium, or other fiber supplements (e.g., Benefiber^® or&#xD;
             Metamucil^®)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy LeJeune, MS, RD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <name_title>Amy LeJeune, MS,RD</name_title>
    <organization>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>diarrhea</keyword>
  <keyword>radiation toxicity</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>stage I uterine sarcoma</keyword>
  <keyword>stage II uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage 0 cervical cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

